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 The N-MOmentum trial: building momentum to advance trial methodology in a rare 
disease 
In Europe a rare disease is defined formally by a prevalence of less than 50/100,000.1 So 
whilst adult MS is not rare, paediatric MS can be considered as such. How do you design a 
trial for a rare or orphan disease? A number of suggestions regarding innovative approaches 
to the design and analysis of trials in this arena have been made,2 but current practice is 
often different and may shy away from implementing novel methodologies.3 We therefore 
commend Bruce Cree and colleagues for developing and, even more importantly 
implementing, a new approach to a clinical trial in Neuromyelitis Optica (NMO) which is 
described in this issue of the MSJ.4 
A cousin inflammatory condition of MS is of course NMO, which has only really split away 
from the main body of MS over the last decade, particularly with the discovery of the anti-
AQP4 antibody. NMO is of major interest to those diagnosing MS because of the phenotypic 
similarities, sharpened by the differences in management. It is a rare disease, with 
prevalence rates of 0.5-4.5/100,000, with geographical variation (Japan versus Europe say). 
As is often the case in medicine, treatments have arisen through clinical judgement, to case 
reports, and then series, with the usual suspects being from the queue of: corticosteroids, 
immunoglobulins, plasma exchange, older immunosuppressants (eg azathioprine) and 
newer designer monoclonal antibodies (eg rituximab). But how to evaluate formally with 
randomised controlled trial (RCT) methodology a new arrival in a rare disease situation? 
What are the tricks of that trade? Matters are compounded by the potential seriousness of 
NMO: paraparesis and blindness stand out. 
Here, the candidate to be evaluated is a new anti-CD19 antibody that depletes B cells and 
the trial is the N-MOmentum study [NCT02200770]. How do they do it and what statistical 
engine are they using? Their starting point, is that the evidence for current therapeutics is 
uneven (American Academy of Neurology class IV), made up of before and after studies, 
without control, and therefore a placebo arm is justified, but that the time spent on placebo 
should be minimised. The judgement of the appropriateness of a placebo arm in this 
condition is of course of great interest and could lead to a lively debate depending on 
practioner preference.5 The ethical dimensions are well aired here. 
In terms of pure trial design, four tactics were incorporated: a time-to-attack primary 
outcome; a short duration trial of 6.5 months; unbalanced (3:1) randomisation; and a futility 
analysis. How do these stack up statistically? 
The use of the time-to-attack endpoint makes a placebo controlled trial feasible since 
treatments can be switched as soon as a relapse occurred, which is close to clinical practice 
and probably more comfortable. Exploitation of this makes placebo controlled trials possible 
in even more vulnerable situations such as paediatric diseases, for example the ongoing 
EARLY PRO-TECT Alport syndrome trial.6 In an event driven trial such as the one suggested, 
statistical power is achieved by observing a certain total number of events, in this case 67 
relapses. The short treatment of follow-up period of 6.5 months might appeal from an 
ethical perspective, but in fact has penalties for the sample size. The authors, using a meta-
analysis of available data, estimate that a total number of 212 patients need to be 
randomized to achieve the target number of relapses. If the follow-up period was say 12 
months rather than 6.5 months, the sample size could be reduced by more than 40%, with 
clear advantages in terms of rates of recruitment and number of centres. It is indeed a 
difficult tightrope to walk to satisfy all the relevant parties. Unbalanced randomization is a 
good move, since it makes participation in the trial more attractive to the patients and 
provides additional and very valuable on-treatment data (such as safety) at a fairly small 
cost in terms of increase in sample size. Futility analysis is a design feature more often seen 
recently because of its obvious appeal from an ethical standpoint but also as a means to 
protect time and resources.7 Furthermore, the interim analysis provides an opportunity to 
adjust the preplanned sample size if the relapse rates turns out to be lower than expected.8 
Finally, in rare conditions we should be more open to incorporating data external to the 
randomized controlled trial. This includes (control) data from previous trials, natural cohort 
studies, and clinical registries. This is termed generalized or cross-design evidence synthesis. 
Technically these are extensions of the standard random effects meta-analysis 
methodology, which itself presents some caveats in rare disease settings.9 However, 
promising examples are starting to appear in the literature.10 How and when these 
techniques will also be applicable in confirmatory settings, will need more discussions with 
stakeholders including regulatory agencies, and most importantly, convincing examples of 
success. 
Ultimately, of course the aim is to find effective treatments for devastating conditions as 
quickly as possible. The N-MOmentum trial, confronts the issues, ethical and statistical head 
on, and the final results and knowledge gained will be eagerly awaited to provide 
momentum to advance trial methodology in rare diseases, both in neurology and elsewhere.  
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